Short answer
Oruka Therapeutics, Inc. (ORKA) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 8.01 (Other Events). IL-23 license expanded to include inflammatory bowel disease and all therapeutic, prophylactic, palliative, and diagnostic uses.
Oruka Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- IL-23 license expanded to include inflammatory bowel disease and all therapeutic, prophylactic, palliative, and diagnostic uses
- ORKA-001 combination dosing in inflammatory bowel disease restricted until June 1, 2028
- ORKA-001 monotherapy dosing in inflammatory bowel disease restricted until June 1, 2030
- Material transaction or change of control accelerates remaining restrictions’ termination to June 1, 2028
- Expanded rights broaden ORKA-001’s potential market while delaying inflammatory bowel disease clinical development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oruka Therapeutics, Inc. 8-K filings
Get the next ORKA 8-K as it lands
Follow ORKA for push alerts, or ask the research agent what this filing means.